PMID- 18635341
OWN - NLM
STAT- MEDLINE
DCOM- 20081027
LR  - 20151119
IS  - 0924-8579 (Print)
IS  - 0924-8579 (Linking)
VI  - 32
IP  - 3
DP  - 2008 Sep
TI  - Linezolid for the treatment of infections caused by Gram-positive pathogens in 
      China.
PG  - 241-9
LID - 10.1016/j.ijantimicag.2008.04.004 [doi]
AB  - In this randomised, double-blind, comparator-controlled, multicentre study 
      conducted in China, 142 hospitalised patients aged 18-75 years with pneumonia 
      (n=80) or complicated skin and soft-tissue infection (cSSTI) (n=62) due to 
      suspected or known Gram-positive pathogens were randomised (1:1) to receive 
      either linezolid 600mg (n=71) or vancomycin 1g in patients aged < or =60 years or 
      0.75g in patients aged >60 years (n=71) intravenously every 12h. The duration of 
      treatment was 10-21 days for patients with pneumonia and 7-21 days for patients 
      with cSSTI. Clinical outcomes were assessed at end-of-treatment (EOT) visit and 
      follow-up (FU) visit 7-28 days post therapy. Staphylococcus aureus was the most 
      common pathogen at baseline and most of these isolates were resistant to 
      meticillin. All isolates were susceptible to linezolid and vancomycin. For the 
      evaluable patients, the effective treatment rate for linezolid was higher than 
      that for vancomycin at EOT (86.9% (53/61) vs. 61.7% (37/60)) and at FU (83.1% 
      (49/59) vs. 64.9% (37/57)). Pathogen eradication rates for the microbiologically 
      evaluable patients at FU were 79.2% (42/53) for linezolid and 61.5% (32/52) for 
      vancomycin. The incidence of drug-related adverse events (AEs) was 25.4% (18/71) 
      for linezolid and 16.9% (12/71) for vancomycin. Four (5.6%) linezolid-treated and 
      eight (11.3%) vancomycin-treated patients discontinued the study drug because of 
      an AE. Linezolid was well tolerated and effective for the treatment of infections 
      caused by Gram-positive pathogens, including meticillin-resistant S. aureus.
FAU - Lin, Dong-Fang
AU  - Lin DF
AD  - Institute of Antibiotics, Huashan Hospital, Fudan University, 12 Wulumuqi Zhong 
      Road, Shanghai 200040, China.
FAU - Zhang, Ying-Yuan
AU  - Zhang YY
FAU - Wu, Ju-Fang
AU  - Wu JF
FAU - Wang, Fu
AU  - Wang F
FAU - Zheng, Jing-Chuan
AU  - Zheng JC
FAU - Miao, Jing-Zhi
AU  - Miao JZ
FAU - Zheng, Li-Ye
AU  - Zheng LY
FAU - Sheng, Rui-Yuan
AU  - Sheng RY
FAU - Zhou, Xin
AU  - Zhou X
FAU - Shen, Hua-Hao
AU  - Shen HH
FAU - Ijzerman, Margaret Marian
AU  - Ijzerman MM
FAU - Croos-Dabrera, Rodney Victor
AU  - Croos-Dabrera RV
FAU - Sheng, Wei
AU  - Sheng W
LA  - eng
PT  - Clinical Trial, Phase III
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20080716
PL  - Netherlands
TA  - Int J Antimicrob Agents
JT  - International journal of antimicrobial agents
JID - 9111860
RN  - 0 (Acetamides)
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Oxazolidinones)
RN  - 6Q205EH1VU (Vancomycin)
RN  - ISQ9I6J12J (Linezolid)
SB  - IM
MH  - *Acetamides/administration & dosage/adverse effects/therapeutic use
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - *Anti-Bacterial Agents/administration & dosage/adverse effects/therapeutic use
MH  - China
MH  - Cross Infection/drug therapy/microbiology
MH  - Double-Blind Method
MH  - Female
MH  - Gram-Positive Bacterial Infections/*drug therapy/microbiology
MH  - Gram-Positive Cocci/*drug effects
MH  - Humans
MH  - Linezolid
MH  - Male
MH  - Middle Aged
MH  - *Oxazolidinones/administration & dosage/adverse effects/therapeutic use
MH  - Pneumonia, Bacterial/drug therapy/microbiology
MH  - Skin Diseases, Bacterial/drug therapy/microbiology
MH  - Soft Tissue Infections/drug therapy/microbiology
MH  - Treatment Outcome
MH  - Vancomycin/administration & dosage/adverse effects/therapeutic use
EDAT- 2008/07/19 09:00
MHDA- 2008/10/28 09:00
CRDT- 2008/07/19 09:00
PHST- 2008/02/01 00:00 [received]
PHST- 2008/03/19 00:00 [revised]
PHST- 2008/04/06 00:00 [accepted]
PHST- 2008/07/19 09:00 [pubmed]
PHST- 2008/10/28 09:00 [medline]
PHST- 2008/07/19 09:00 [entrez]
AID - S0924-8579(08)00161-1 [pii]
AID - 10.1016/j.ijantimicag.2008.04.004 [doi]
PST - ppublish
SO  - Int J Antimicrob Agents. 2008 Sep;32(3):241-9. doi: 
      10.1016/j.ijantimicag.2008.04.004. Epub 2008 Jul 16.